Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...
The Diabetic Retinopathy Clinical Research Network (DRCR.net) conducted a comparative effectiveness trial evaluating the prevalence of persistent diabetic macular edema (DME) and its effect on visual ...
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...
In patients with proliferative diabetic retinopathy (PDR), treatment with panretinal photocoagulation (PRP) followed by anti–vascular endothelial growth factor (anti-VEGF) appears to increase ...
4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of ...
Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...
Please provide your email address to receive an email when new articles are posted on . One specialist proposed that new-generation anti-VEGFs show better efficacy. Another said there is a lack of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results